ResearchMoz

Pediatric Vaccines Market to 2017- Strategic Focus on Partnering as Licensing and Co-Development Accounted for 69% of Deal-Making Activity from 2004-2011

GBI Research
Published Date » 2012-03-14
No. Of Pages » 127

GBI Research, the leading business intelligence provider, has released its latest research, “Pediatric Vaccines Market to 2017Strategic Focus on Partnering as Licensing and Co-Development Accounted for 69% of Deal-Making Activity from 2004-2011”, which provides insights into global pediatric vaccines market forecast until 2017. The report provides an in-depth analysis of six vaccines which include hepatitis A, hepatitis B, polio, rotavirus, Mumps, Measles and Rubella (MMR) and Diphtheria, Tetanus and Pertussis (DTaP). The report also examines the immunization schedules for the covered vaccines. In addition, the report also includes insights into the vaccines Research and Development (R&D) pipeline. 

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. 

GBI Research analysis shows that the overall global pediatric vaccines market was valued at $14 billion in 2010. The market is expected to witness a growth at a CAGR of 11.5% for the forecast period and will reach $24.3 billion by 2017. The global market revenues are expected to increase due to the introduction of new molecules which are currently in the regulatory filing stage and those in the later stages of development. The top pharmaceutical companies in the vaccines market are – GlaxoSmithKline, Sanofi, Pfizer, Novartis AG., Merck & co. Inc and SP-MSD. Approximately 88% of the market is covered by the above six companies.

Scope

  • Data and analysis on the global pediatric vaccines market
  • Annualized market data for the vaccines market from 2007 to 2017
  • Key drivers and restraints that have had a significant impact on the market
  • The competitive landscape of the global vaccines market
  • Key M&A activities, licensing agreements and co-development deals that took place in the pediatric vaccines market

Reasons to buy

  • Align your product portfolio to the markets with high growth potential.
  • Develop market-entry and market expansion strategies by identifying the potential region and therapeutic segments poised for strong growth.
  • Device a more tailored country strategy through the understanding of key drivers and barriers of vaccines market.
  • Develop key strategic initiatives by understanding the key focus areas and leading companies.
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.
Table of Contents

1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 6
1.2 List of Figures 8

2 Pediatric Vaccines Market to 2017 - Introduction 10
2.1 GBI Research Report Guidance 11

3 Pediatric Vaccines Market to 2017 - Market Overview 12
3.1 Vaccine Preventable Diseases 12
3.2 Vaccine Manufacturing Process 13
3.3 Determinants of Immunization Coverage 13
3.3.1 Immunization Programs 13
3.3.2 Public Private Partnerships 14
3.3.3 Production Capacity 14
3.3.4 Reimbursements 14

4 Pediatric Vaccines Market to 2017 - Global Vaccine Market 15
4.1 Market Forecasts 15
4.1.1 Market Share by Disease Sector 16
4.1.2 Market Share by Geography 17
4.2 Average Cost of Vaccination per Child 17
4.3 Target Population 18
4.3.1 Immunization Coverage 19
4.4 Drivers and Barriers of the Pediatric Vaccines Market 20
4.4.1 Drivers for Pediatric Vaccine Market 20
4.4.2 Barriers for Pediatric Vaccines Market 21

5 Global Pediatric Vaccines Market to 2017 - Geographical Landscape 22
5.1 The US 22
5.1.1 Market Overview 22
5.1.2 Market Forecasts 22
5.1.3 Average Cost of Vaccination 23
5.1.4 Immunization Coverage 25
5.1.5 Immunization Schedule 26
5.1.6 Regulatory Framework 27
5.1.7 Vaccine Procurement 28
5.2 Top Five Countries of Europe 29
5.2.1 Market Overview 29
5.2.2 Market Forecasts 29
5.2.3 Average Cost of Vaccination per Child 30
5.2.4 Immunization Coverage 32
5.2.5 The UK 33
5.2.6 France 34
5.2.7 Germany 35
5.2.8 Italy 36
5.2.9 Spain 37
5.3 Rest of the World 38
5.3.1 Market Overview 38
5.3.2 Market Forecasts 38
5.3.3 Average Cost of Vaccination per Child 39
5.3.4 Immunization Coverage 41
5.3.5 Immunization Schedule 42
5.3.6 Regulatory Framework 42
5.3.7 Vaccine Procurement 42

6 Global Pediatric Vaccines Market to 2017 - Therapeutic Landscape 43
6.1 Hepatitis A 43
6.1.1 Overview 43
6.1.2 Market Forecasts 43
6.1.3 Average Cost of Vaccination 44
6.1.4 Target Population 45
6.1.5 Marketed Products for Hepatitis A 46
6.2 Hepatitis B 48
6.2.1 Overview 48
6.2.2 Market Forecasts 49
6.2.3 Average Cost of Vaccination 50
6.2.4 Target Population 51
6.2.5 Marketed Products for Hepatitis B 52
6.3 Polio 55
6.3.1 Overview 55
6.3.2 Market Forecasts 55
6.3.3 Average Cost of Vaccination 56
6.3.4 Target Population 57
6.3.5 Marketed Products for Polio 58
6.4 Rotavirus 59
6.4.1 Overview 59
6.4.2 Market Forecasts 59
6.4.3 Average Cost of Vaccination 60
6.4.4 Target Population 61
6.4.5 Product Analysis 62
6.4.6 Marketed Products for Rotavirus 62
6.5 DTaP 64
6.5.1 Overview 64
6.5.2 Market Forecasts 64
6.5.3 Average Cost of Vaccination 65
6.5.4 Target Population 66
6.5.5 Marketed Products for DTaP 67
6.6 MMR 69
6.6.1 Overview 69
6.6.2 Market Forecasts 69
6.6.3 Average Cost of Vaccination 70
6.6.4 Target Population 71
6.6.5 Marketed Products for MMR 72

7 Global Pediatric Vaccines Market to 2017 - Product Pipeline Analysis 74
7.1 Research and Development Pipeline by Phase 74
7.2 Research and Development Pipeline by Indication 75
7.3 Research and Development Pipeline - Hepatitis A Vaccines 76
7.3.1 Overview 76
7.3.2 Pipeline by Clinical Phases of Development 77
7.4 Research and Development Pipeline - Hepatitis B Vaccines 77
7.4.1 Overview 77
7.4.2 Pipeline by Clinical Phases of Development 78
7.5 Research and Development Pipeline - Polio Vaccines 83
7.5.1 Overview 83
7.5.2 Pipeline by Clinical Phases of Development 84
7.6 Research and Development Pipeline - Rotavirus Vaccines 86
7.6.1 Overview 86
7.6.2 Pipeline by Clinical Phases of Development 87
7.7 Research and Development Pipeline - DTaP Vaccines 88
7.7.1 Overview 88
7.7.2 Pipeline by Clinical Phases of Development 89
7.8 Research and Development Pipeline - MMR Vaccines 92
7.8.1 Overview 92
7.8.2 Pipeline by Clinical Phases of Development 93

8 Global Pediatric Vaccines Market - Competitive Landscape 94
8.1 Overview 94
8.2 Company Profiling 94
8.2.1 Novartis 94
8.2.2 GlaxoSmithKline (GSK) 96
8.2.3 Sanofi Pasteur MSD 97
8.2.4 Merck 99
8.2.5 Pfizer 100

9 Global Pediatric Vaccines Market to 2017 - Strategic Consolidations 102
9.1 Segmentation by Type 102
9.2 Segmentation by Year 103
9.3 Mergers and Acquisitions 104
9.3.1 Overview 104
9.3.2 M&A Deals by Indication 105
9.3.3 M&A Deals by Year 106
9.3.4 M&A Deals by Geography 107
9.3.5 M&A Deals by Value 108
9.3.6 Major Mergers and Acquisitions (M&A) 109
9.4 Licensing Agreements 110
9.4.1 Overview 110
9.4.2 Licensing Agreements by Indication 110
9.4.3 Licensing Agreements by Year 112
9.4.4 Licensing Agreements by Geography 113
9.4.5 Licensing Agreements by Value 114
9.4.6 Major Licensing Agreements 115
9.5 Co-Development Deals 117
9.5.1 Overview 117
9.5.2 Co-Development Deals by Indication 117
9.5.3 Co-Development Deals by Year 118
9.5.4 Co-Development Deals by Geography 119
9.5.5 Major Co-Development Deals 120

10 Global Pediatric Vaccines Market to 2017 - Appendix 122
10.1 Market Definitions 122
10.2 Abbreviations 122
10.3 Research Methodology 123
10.3.1 Global Pediatric Vaccines Market 123
10.3.2 Geographical Landscape 124
10.3.3 Therapeutic Landscape 125
10.3.4 Competitive Landscape 125
10.3.5 Pipeline Analysis 126
10.3.6 Strategic Consolidations 126
10.4 Contact Us 126
10.5 Disclaimer 126
10.6 Sources 127

List of Tables


Table 1: Pediatric Vaccine Market, Global, Vaccine Preventable Diseases, 2011 12
Table 2: Pediatric Vaccines Market, Global, Revenue Forecasts ($bn), 2007-2017 15
Table 3: Pediatric Vaccines Market, Global, Target Population (million), 2007-2017 18
Table 4: Pediatric Vaccines Market, Global, Immunization Coverage, (%), 2008-2010 19
Table 5: Pediatric Vaccines Market, The US, Revenue Forecasts ($bn), 2007-2017 22
Table 6: Pediatric Vaccines Market, The US, Average Cost of Vaccination Per Child ($), 2011 24
Table 7: Pediatric Vaccines Market, The US, Immunization Coverage, (%), 2008-2010 25
Table 8: Pediatric Vaccines Market, Top Five Countries of Europe, Average Cost of Vaccination Per Child ($), 2010 31
Table 9: Pediatric Vaccines Market, Top Five Countries of Europe, Immunization Coverage, %, 2008-2010 32
Table 10: Pediatric Vaccines Market, Rest of the World, Revenue Forecasts ($bn), 2007-2017 39
Table 11: Pediatric Vaccines Market, Rest of the World, Average Cost of Vaccination Per Child ($), 2011 40
Table 12: Pediatric Vaccines Market, Rest of the World, Immunization Coverage, (%), 2008-2010 41
Table 13: Hepatitis A Vaccines Market, Global, Revenue Forecasts ($m), 2007-2017 43
Table 14: Hepatitis A Vaccines Market, Global, Average Cost of Vaccination($) , 2007-2017 44
Table 15: Hepatitis A Vaccines Market, Global, Target Population (million), 2007-2017 45
Table 16: Hepatitis B Vaccines Market, Global, Revenue Forecasts ($m), 2007-2017 49
Table 17: Hepatitis B Vaccines Market, Global, Average Cost of Vaccination, ($), 2007-2017 50
Table 18: Hepatitis B Vaccines Market, Global, Target Population (million) , 2007-2017 51
Table 19: Polio Vaccines Market, Global, Revenue Forecasts ($m), 2007-2017 55
Table 20: Polio Vaccines Market, Global, Average Cost of Vaccination ($) , 2007-2017 56
Table 21: Polio Vaccines Market, Global, Target Population (million), 2007-2017 57
Table 22: Rotavirus Vaccines Market, Global, Revenue Forecasts ($bn), 2007-2017 59
Table 23: Rotavirus Vaccines Market, Global, Average Cost of Vaccination ($), 2007-2017 60
Table 24: Rotavirus Vaccines Market, Global, Target Population (million), 2007-2017 61
Table 25: Rotavirus Vaccines Market, Global, Comparison of Key Products, 2011 62
Table 26: DTaP Vaccines Market, Global, Revenue Forecasts ($m), 2007-2017 64
Table 27: DTaP Vaccines Market, Global, Average Cost of Vaccination, ($), 2007-2017 65
Table 28: DTaP Vaccines Market, Global, Target Population (million), 2007-2017 66
Table 29: MMR Vaccines Market, Global, Revenue Forecasts ($bn), 2007–2017 69
Table 30: MMR Vaccines Market, Global, Average Cost of Vaccination($), 2007–2017 70
Table 31: MMR Vaccines Market, Global, Target Population (million), 2007-2017 71
Table 32: Pediatric Vaccines Market, Global, Pipeline Molecules by Phase, (%), 2011 74
Table 33: Pediatric Vaccines Market, Global, Pipeline Molecules by Indication, (%), 2011 75
Table 34: Hepatitis A Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011 76
Table 35: Hepatitis A Therapeutics Market, Global, Preclinical Pipeline Molecules, 2011 77
Table 36: Hepatitis A Therapeutics Market, Global, Phase III Molecules, 2011 77
Table 37: Hepatitis B Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011 78
Table 38: Hepatitis B Therapeutics Market, Global, Preclinical Pipeline Molecules, 2011 78
Table 39: Hepatitis B Therapeutics Market, Global, Phase I Molecules, 2011 79
Table 40: Hepatitis B Therapeutics Market, Global, Phase II Molecules, 2011 80
Table 41: Hepatitis B Therapeutics Market, Global, Phase III Molecules, 2011 82
Table 42: Hepatitis B Therapeutics Market, Global, NDA Filed Molecules, 2011 83
Table 43: Polio Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011 84
Table 44: Polio Therapeutics Market, Global, Phase II Molecules, 2011 84
Table 45: Polio Therapeutics Market, Global, Phase III Molecules, 2011 85
Table 46: Rotavirus Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011 86
Table 47: Rotavirus Therapeutics Market, Global, Pre-Clinical Molecules, 2011 87
Table 48: Rotavirus Therapeutics Market, Global, Phase I Molecules, 2011 87
Table 49: Rotavirus Therapeutics Market, Global, Phase II Molecules, 2011 87
Table 50: Rotavirus Therapeutics Market, Global, Phase III Molecules, 2011 87
Table 51: DTaP Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011 88
Table 52: DTaP Therapeutics Market, Global, Preclinical Molecules, 2011 89
Table 53: DTaP Therapeutics Market, Global, Phase I Molecules, 2011 89
Table 54: DTaP Therapeutics Market, Global, Phase II Molecules, 2011 90
Table 55: DTaP Therapeutics Market, Global, Phase III Molecules, 2011 91
Table 56: DTAP Therapeutics Market, Global, NDA Filed Molecules, 2011 91
Table 57: MMR Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011 92
Table 58: MMR Therapeutics Market, Global, Preclinical Molecules, 2011 93
Table 59: MMR Therapeutics Market, Global, Phase II Molecules, 2011 93
Table 60: MMR Therapeutics Market, Global, Phase II Molecules 93
Table 61: Pediatric Vaccines Market, Global, Deals by Type, (%), 2004-2011 102
Table 62: Pediatric Vaccines Market, Global, Deals by Geography, (%), 2004-2011 103
Table 63: Pediatric Vaccines Market, Global, M&A Deals, 2004-2011 104
Table 64: Pediatric Vaccines Market, Global, M&A Deals by Indication (%), 2004-2011 105
Table 65: Pediatric Vaccines Market, Global, M&A Deals by Year, 2004-2011 106
Table 66: Pediatric Vaccines Market, Global, M&A Deals by Geography (%), 2004-2011 107
Table 67: Pediatric Vaccines Market, Global, M&A Deals by Value (%), 2004-2011 108
Table 68: Pediatric Vaccines Market, Global, Major M&A Deals, 2004–2011 109
Table 69: Pediatric Vaccines Market, Global, Licensing Agreements by Indication (%), 2004-2011 111
Table 70: Pediatric Vaccines Market, Global, Licensing Agreements by Year, 2004-2011 112
Table 71: Pediatric Vaccines Market, Global, Licensing Agreements by Geography (%), 2004-2011 113
Table 72: Pediatric Vaccines Market, Global, Licensing Agreements by Value (%), 2004-2011 114
Table 73: Pediatric Vaccines Market, Global, Major Licensing Deals, 2004–2011 115
Table 74: Pediatric Vaccines Market, Global, Co-Development Deals by Indication (%), 2004-2011 117
Table 75: Pediatric Vaccines Market, Global, Co-Development Deals by Year, 2004-2011 118
Table 76: Pediatric Vaccines Market, Global, Co-Development Deals by Geography, 2004-2011 119
Table 77: Pediatric Vaccines Market, Global, Major Co-Development Deals, 2004–2011 120

List of Figures


Figure 1:  Pediatric Vaccines Market, Global, Manufacturing Process, 2011 13
Figure 2: Pediatric Vaccines Market, Global, Revenue Forecasts ($bn), 2007-2017 15
Figure 3: Pediatric Vaccines Market, Global, Market Share by Disease Segment, 2010 16
Figure 4: Pediatric Vaccines Market, Global, Market Share by Geography, 2010 17
Figure 5: Pediatric Vaccines Market, Global, Target Population (million), 2007-2017 18
Figure 6: Pediatric Vaccines Market, Global, Immunization Coverage, (%), 2008-2010 19
Figure 7: Pediatric Vaccines Market, Global, Growth Drivers and Barriers, 2011 20
Figure 8: Pediatric Vaccines Market, The US, Revenue Forecasts ($bn), 2007-2017 22
Figure 9: Pediatric Vaccines Market, The US, Average Cost of Vaccination Per Child ($), 2011 23
Figure 10: Pediatric Vaccines Market, The US, Immunization Coverage, (%), 2008-2010 25
Figure 11: Pediatric Vaccines Market, The US, Immunization Schedule, 2011 26
Figure 12: Pediatric Vaccines Market. The US, Vaccine Development and Approval Process, 2011 27
Figure 13: Pediatric Vaccines Market, The US, Distribution of Vaccine Procurement (%) , 2011 28
Figure 14: Pediatric Vaccines Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2007-2017 29
Figure 15: Pediatric Vaccines Market, Top Five Countries of Europe, Average Cost of Vaccination Per Child ($), 2011 30
Figure 16: Pediatric Vaccines Market, Top Five Countries of Europe, Immunization Coverage, (%), 2008-2010 32
Figure 17: Pediatric Vaccines Market, The UK, Immunization Schedule, 2011 33
Figure 18: Pediatric Vaccines Market, France, Immunization Schedule, 2011 34
Figure 19: Pediatric Vaccines Market, Germany, Immunization Schedule, 2011 35
Figure 20: Pediatric Vaccines Market, Italy, Immunization Schedule, 2011 36
Figure 21: Pediatric Vaccines Market, Spain, Immunization Schedule, 2011 37
Figure 22: Pediatric Vaccines Market, Rest of the World, Revenue Forecasts ($bn), 2007-2017 38
Figure 23: Pediatric Vaccines Market, Rest of the World, Average Cost of Vaccination Per Child ($), 2011 39
Figure 24: Pediatric Vaccines Market, Rest of the World, Immunization Coverage, (%), 2008-2010 41
Figure 25: Hepatitis A Vaccines Market, Global, Revenue Forecasts ($m), 2007-2017 43
Figure 26: Hepatitis A Vaccines Market, Global, Average Cost of Vaccination ($), 2007-2017 44
Figure 27: Hepatitis A Vaccines Market, Global, Target Population (million), 2007-2017 45
Figure 28: Hepatitis B Vaccines Market, Global, Revenue Forecasts ($m), 2007-2017 49
Figure 29: Hepatitis B Vaccines Market, Global, Average Cost of Vaccination, ($), 2007-2017 50
Figure 30: Hepatitis B Vaccines Market, Global, Target Population (million) , 2007-2017 51
Figure 31: Polio Vaccines Market, Global, Revenue Forecasts ($m), 2007-2017 55
Figure 32: Polio Vaccines Market, Global, Average Cost of Vaccination, ($), 2007-2017 56
Figure 33: Polio Vaccines Market, Global, Target Population (million), 2007-2017 57
Figure 34: Rotavirus Vaccines Market, Global, Revenue Forecasts ($bn), 2007-2017 59
Figure 35: Rotavirus Vaccines Market, Global, Average Cost of Vaccination ($), 2007-2017 60
Figure 36: Rotavirus Vaccines Market, Global, Target Population (million), 2007-2017 61
Figure 37: DTaP Vaccines Market, Global, Revenue Forecasts ($m), 2007-2017 64
Figure 38: DTaP Vaccines Market, Global, Average Cost of Vaccination($), 2007-2017 65
Figure 39: DTaP Vaccines Market, Global, Target Population (million), 2007-2017 66
Figure 40: MMR Vaccines Market, Global, Revenue Forecasts ($bn), 2007-2017 69
Figure 41: MMR Vaccines Market, Global, Average Cost of Vaccination ($), 2007-2017 70
Figure 42: MMR Vaccines Market, Global, Target Population (million), 2007-2017 71
Figure 43: Pediatric Vaccines Market, Global, Pipeline Molecules by Phase, (%), 2011 74
Figure 44: Pediatric Vaccines Market, Global, Pipeline Molecules by Indication, (%), 2011 75
Figure 45: Hepatitis A Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011 76
Figure 46: Hepatitis B Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011 77
Figure 47: Polio Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011 83
Figure 48: Rotavirus Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011 86
Figure 49: DTaP Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011 88
Figure 50: MMR Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011 92
Figure 51: Pediatric Vaccines Market, Global, Novartis, Company Profile, 2011 94
Figure 52: Pediatric Vaccines Market, Global, Novartis, SWOT Analysis, 2011 95
Figure 53: Pediatric Vaccines Market, Global, GlaxoSmithKline, Company Profile, 2011 96
Figure 54: Pediatric Vaccines Market, Global, GlaxoSmithKline, SWOT Analysis, 2011 97
Figure 55: Pediatric Vaccines Market, Global, Sanofi Pasteur MSD, Company Profile, 2011 97
Figure 56: Pediatric Vaccines Market, Global, Sanofi Pasteur MSD, SWOT Analysis, 2011 98
Figure 57: Pediatric Vaccines Market, Global, Merck, Company Profile, 2011 99
Figure 58: Pediatric Vaccines Market, Global, Merck, SWOT Analysis, 2011 100
Figure 59: Pediatric Vaccines Market, Global, Pfizer, Company Profile, 2011 100
Figure 60: Pediatric Vaccines Market, Global, Pfizer, SWOT Analysis, 2011 101
Figure 61: Pediatric Vaccines Market, Global, Deals by Type, (%), 2004-2011 102
Figure 62: Pediatric Vaccines Market, Global, Deals by Geography, (%), 2004-2011 103
Figure 63: Pediatric Vaccines Market, Global, M&A Deals, 2004-2011 104
Figure 64: Pediatric Vaccines Market, Global, M&A Deals by Indication (%), 2004-2011 105
Figure 65: Pediatric Vaccines Market, Global, M&A Deals by Year, 2004-2011 106
Figure 66: Pediatric Vaccines Market, Global, M&A Deals by Geography (%), 2004-2011 107
Figure 67: Pediatric Vaccines Market, Global, M&A Deals by Value (%), 2004-2011 108
Figure 68: Pediatric Vaccines Market, Global, Licensing Agreements by Indication (%), 2004-2011 110
Figure 69: Pediatric Vaccines Market, Global, Licensing Agreements by Year, 2004-2011 112
Figure 70: Pediatric Vaccines Market, Global, Licensing Agreements by Geography (%), 2004-2011 113
Figure 71: Pediatric Vaccines Market, Global, Licensing Agreements by Value (%), 2004-2011 114
Figure 72: Pediatric Vaccines Market, Global, Co-Development Deals by Indication (%), 2004-2011 117
Figure 73: Pediatric Vaccines Market, Global, Co-Development Deals by Year, 2004-2011 118
Figure 74: Pediatric Vaccines Market, Global, Co-Development Deals by Geography, 2004-2011 119

Upcoming Reports:

Cell Based Assays Market - Global Industry Analysis, Market Share, Size, Growth, Trends, And Forecast, 2012 - 2018
By - Transparency Market Research
The term ‘cell based assay’ refers to the use of live cells to test the effect of a foreign substance on the functionalities and behavior of a cell. These cell based assays are the most accurate method of cell testing, due to the fact that live cells are utilized for experiments.  It is used for determining factors like cell toxicity, cell proliferation, motility, and cell morphology. The global market for cell based assays is expected to reach an estimated value of USD 1.55 billion in 2018.  The growing investments made by pharmaceutical companies in...
Policy Management Software Market - Global Industry Size, Market Share, Trends, Analysis And Forecasts 2012 - 2018
By - Transparency Market Research
Policy management software market is gaining momentum as more number of network operators are using policy solutions to generate revenues from new services and to optimize the subscriber experience. Policy management software industry is set to witness strong growth rate in the near future with increasing policy management applications and new vendors. The global sales of policy management software reached $589 million during 2011 and expected to go beyond $1.9 billion by 2016. Wireless market is the most popular segments of policy management software industry. Most network...
Natural Source Vitamin E Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Vitamin E is a significant antioxidant which helps against free-radicals and it can be conserved longer by the tissues in the body as compared to man-made vitamin E. Natural vitamins has seen increased demand from the end users in recent past. Natural source vitamin E includes tocopherols and tocotrienols. Apprehensions related to toxic chemicals in products such as food products, beverages, pharmaceuticals and personal care have driven the rapid growth in sales of natural vitamin E. Supplements for nutrition and food & beverage enrichment are the present primary markets for natural...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Top End Stereo Systems Maker Harman Targets Chinese Auto Market
Apr 22, 2014  
Harman, the U.S.-based audio company that is best known as the provider of automobile stereos for top-end car models such as Mercedes-Benz, BMW and Ferrari, has said that it has signed agreements with two leading Chinese automakers—Chang’An and Geely. The company, that is associated with premium infotainment systems for leading auto makers, said that these new contracts...
Scientists Identify Cure for Dengue
Apr 18, 2014  
In a breakthrough discovery that can change the way dengue is treated, scientists have identified a drug target for the deadly dengue viruses. This discovery may help pave the way for discovery of vaccines that can cure this condition that affects nearly 390 million people throughout the world each year.  Scientists have used a new technique for this discovery to show that a region...
India is Facing a Cancer Crisis
Apr 15, 2014  
India is currently facing a cancer crisis – reports a recent research carried out at the King’s college London, in collaboration with the Tata Memorial Cancer Centre, Mumbai.  The reasons estimated for this crisis comprise of increasing rates of smoking, unequal access to proper treatment and belated diagnosis.  Every year, India witnesses around one...
Microparticle Tags to Check Counterfeit Goods Invented
Apr 14, 2014  
Researchers from the Massachusetts Institute of Technology have invented a new set of microparticles that can easily be read by smartphones and establish the authenticity of currency, electronic items and luxury goods.  This strategy is among those countless measures taken by big brands and companies to label their legitimate products in order to stop illegal copies of the...
USFDA Approves Lupins Generic Diabetic Drug
Apr 10, 2014  
The United States Food and Drugs Administration (USFDA) has finally approved Lupin Pharmaceuticals Inc (LPI), the American subsidiary of Indian drug manufacturers Lupin Ltd, to sell Pioglitazone Tablets in the U.S market. The approval has been granted first for fiscal 2015.  Pioglitazone is a generic medicine used for managing diabetes and is a version of Actos tablets...